Merck & Co., Inc.

NYSE: MRK
$81.90
-$0.86 (-1.0%)
Closing price September 29, 2020
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Monday's top analyst upgrades and downgrades included AbbVie, DuPont, Etsy, Expedia, Exxon Mobile, Kansas City Southern, Merck, Microsoft, Pinterest, Qualcomm, Visa and Yum! Brands.
When Merck & Co. (NYSE: MRK) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37 and...
24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week, including Apple, Boeing, Exxon, McDonald's and Visa.
Merck shares jumped on Tuesday after the company announced that it has made deals to develop drugs in the fight against COVID-19.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering, investors were not thrilled about this quarter for these two...
Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's what to expect.
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. wanted to see which companies have the best chance at not having to lower their dividends at all and those that almost certainly will retain much of their current dividends in a...
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.